China’s new economic plan sets stage for future reforms affecting biopharma

China’s new five-year economic plan likely means many investors in the country’s biotechs may have to get used to the volatility that has tortured biotech and tech shares recently as new policies affecting the sector take shape and find their way into practice. 

The plan, as is common for those from the Communist Party’s Central Committee at this stage, is very high level, calling for the promotion of legislation in areas such as biosecurity, public health and technological innovation. Released Thursday night China time, it also cites the need for revisions to the laws governing infectious diseases and public health emergencies, and increased enforcement of laws related to medicine and public health...